| Symbol | PSNL |
|---|---|
| Name | PERSONALIS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 6600 DUMBARTON CIRCLE, FREMONT, California, 94555, United States |
| Telephone | +1 650 - 752-1300 |
| Fax | — |
| — | |
| Website | https://www.personalis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001527753 |
| Description | Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Personalis, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-350856 <b>Size:</b> 8 KB
Read moreNew Form SCHEDULE 13G/A - Personalis, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003485 <b>Size:</b> 11 KB
Read morePersonalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Read more$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)
Read moreNew Form SCHEDULE 13D/A - Personalis, Inc. <b>Filed:</b> 2026-07-21 <b>AccNo:</b> 0001193125-26-310289 <b>Size:</b> 29 KB
Read moreNew Form 425 - Personalis, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001193125-26-309106 <b>Size:</b> 65 KB
Read moreNew Form 425 - Personalis, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001193125-26-309096 <b>Size:</b> 62 KB
Read moreNew Form 425 - Personalis, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001193125-26-309093 <b>Size:</b> 127 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06705361 | Ice Bag, TR Band, and Air Compression Effects on Radial Line Removal Outcomes i… | Na | Cardiac Disease | Not_Yet_Recruiting | 2024-11-25 | 2025-03-25 | ClinicalTrials.gov |
| NCT06230185 | CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | TNBC - Triple-Negative Breast Cancer | Recruiting | 2023-11-09 | 2025-12-31 | ClinicalTrials.gov |
| NCT05414032 | Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HP… | Phase2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Recruiting | 2023-07-12 | 2028-07-01 | ClinicalTrials.gov |
| NCT05695976 | GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | — | Glioblastoma | Suspended | 2023-04-18 | 2029-01-01 | ClinicalTrials.gov |
| NCT05197322 | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer | Phase2 | Adenocarcinoma of the Colon | Recruiting | 2022-07-20 | 2029-07-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Transparent Radial Artery Band (Screw-Type) | Other | Approved | Cardiac Disease | NOT_YET_RECRUITING | NCT06705361 |
| 68Ga-FAPI-46-PET-CT | Other | Approved | Triple Negative Breast Cancer | RECRUITING | NCT06225505 |
| ctDNA monitoring | Other | Approved | Triple Negative Breast Cancer | RECRUITING | NCT06225505 |
| AZD2936 | Other | Phase PHASE2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | RECRUITING | NCT05414032 |
| Pembrolizumab | Other | Phase PHASE2 | Adenocarcinoma of the Colon | RECRUITING | NCT05197322 |
| Pembrolizumab | Other | Phase PHASE2 | Adenocarcinoma of the Colon | RECRUITING | NCT05197322 |
| Transparent Radial Artery Band (Screw-Type) | DEVICE | Approved | Cardiac Disease | NOT_YET_RECRUITING | NCT06705361 |
| AZD2936 | BIOLOGICAL | Phase PHASE2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | RECRUITING | NCT05414032 |